The full content of Annals is available to subscribers

Subscribe/Learn More  >
Medicine and Public Policy |

Cost Effectiveness of Colorectal Cancer Screening in the Elderly

Judith L. Wagner, PhD; Roger C. Herdman, MD; and Sandeep Wadhwa, BA
[+] Article, Author, and Disclosure Information

Requests for Reprints: Roger C. Herdman, MD, U.S. Congress, Office of Technology Assessment, Washington, DC 20510-8025.

Current Author Addresses: Drs. Wagner and Herdman: U.S. Congress Office of Technology Assessment, Washington, DC 20510-8025.

Mr. Wadhwa: 420 East 70th St, New York, NY 10021.

Ann Intern Med. 1991;115(10):807-817. doi:10.7326/0003-4819-115-10-807
Text Size: A A A

Objective: To assess the cost effectiveness of a periodic program of colorectal cancer screening in the elderly.

Design: A model was constructed of four strategies for the periodic screening of persons 65 to 85 years of age. The effect of each strategy on life expectancy and health care costs was estimated under assumptions that were uniformly unfavorable to screening. Cost and added years of life were discounted at 5% per year. Cost per year of life gained from screening was calculated for each screening strategy.

Data Sources: Assumptions used in the model were based on a review of pertinent studies; those studies with results more unfavorable to screening were given more weight. Strengths and weaknesses of studies are discussed.

Main Results: A program of annual fecal occult blood testing (FOBT) in the elderly would detect at least 17% of the expected cases of cancer and could cost $35 000 per year of life saved. Screening schedules that include periodic sigmoidoscopy would prevent more cases of cancer but could cost between $43 000 and $47 000 per year of life gained. These estimates are based on uncertain assumptions, but results were not extremely sensitive to further relaxation of the values of the most uncertain assumptions. In no case did the cost per year of life gained from annual FOBT exceed $55 000 or did the cost per year of life gained from FOBT with sigmoidoscopy every 5 years exceed $61 000.

Conclusions: Although colorectal cancer screening is costly in the aggregate, its potential medical benefits make it a reasonably cost-effective preventive intervention for the elderly.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.